MCID: RHM027
MIFTS: 58

Rheumatic Disease malady

Categories: Cardiovascular diseases, Immune diseases

Aliases & Classifications for Rheumatic Disease

Summaries for Rheumatic Disease

Disease Ontology : 12 A hypersensitivity reaction type II disease that involves inflammation or pain in the muscles, joints, or fibrous tissue.

MalaCards based summary : Rheumatic Disease, also known as rheumatic diseases, is related to hepatitis and tuberculosis, and has symptoms including musculoskeletal symptom, myalgia and joint symptom. An important gene associated with Rheumatic Disease is TNF (Tumor Necrosis Factor), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs Methotrexate and Hydroxychloroquine have been mentioned in the context of this disorder. Affiliated tissues include testes, bone and t cells, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and hematopoietic system

Related Diseases for Rheumatic Disease

Diseases related to Rheumatic Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 314)
id Related Disease Score Top Affiliating Genes
1 hepatitis 30.4 HLA-DRB1 IFNG IL10 TNF
2 tuberculosis 30.3 IL10 IL1B TNF
3 neuropathy 29.7 CRP IL1B TNF
4 burns 29.5 IFNG IL10 TNF
5 rheumatoid arthritis 29.3 CRP HLA-DRB1 HMGB1 IFNG IL10 IL1B
6 myocardial infarction 29.3 CRP IL10 IL1B PTGS1 PTGS2 TNF
7 macrophage activation syndrome 11.1
8 palindromic rheumatism 11.1
9 enthesopathy 11.1
10 rheumatic pulmonary valve disease 10.9
11 spondyloarthropathy 1 10.9
12 tricuspid valve disease 10.8
13 mitral valve disease 10.8
14 juvenile spondyloarthropathy 10.7
15 intussusception 10.4 IL1B TNF
16 cataract 10.4 CRP IL1B TNF
17 swine influenza 10.4 CRP HLA-DRB1 TNF
18 pyloric stenosis, infantile hypertrophic, 2 10.3 CRP IL1B TNF
19 amyotrophic lateral sclerosis type 14 10.3 IFNG IL1B TNF
20 pyridoxal 5'-phosphate-dependent epilepsy 10.3 IL10 TNF
21 warthin tumor 10.3 IL1B IL1R1 TNF
22 distal trisomy 14q 10.3 HLA-DRB1 IFNG TNF
23 hypertropia 10.3 CRP IFNG TNF
24 urticaria 10.3 CRP IL1B TNF
25 clostridium difficile colitis 10.3 HLA-DRB1 IFNG TNF
26 splenic artery aneurysm 10.3 IL1B TNF TRIM21
27 angiomatosis, diffuse corticomeningeal, of divry and van bogaert 10.3 HLA-DRB1 HMGB1 TNF
28 bile duct signet ring cell carcinoma 10.3 CRP IL1R1 TNF
29 cerebrum cancer 10.3 CRP IL1B VCAM1
30 cinca syndrome 10.3 CRP IL1B IL1R1
31 pancreas lymphoma 10.3 CRP IL1B TNF
32 strawberry gallbladder 10.3 CRP IFNG TNF
33 motility-related diarrhea 10.3 HLA-DRB1 IL1B TNF
34 giant cell glioblastoma 10.3 IFNG IL1B IL1R1
35 functional gastric disease 10.3 CRP IL1R1 TNF
36 blepharochalasis 10.3 CRP IL1B TNF
37 keratoconus 10.3 IL1B IL1R1 TNF
38 right ventricle hypoplasia 10.3 HLA-DRB1 TNF VCAM1
39 benign deep fibrous histiocytoma 10.3 HLA-DRB1 IFNG TNF
40 pericholangitis 10.3 CRP HMGB1 TNF
41 parametritis 10.3 IFNG IL2RA TNF
42 human immunodeficiency virus infectious disease 10.3 CRP HLA-DRB1 IL1B TNF
43 plantar wart 10.3 IFNG IL10 TNF
44 nasopharyngitis 10.3 IFNG IL1B TNF
45 megaloblastic anemia 10.3 CRP IL10 IL1B
46 gonococcal endophthalmia 10.3 IL10 IL1B TNF
47 glucose intolerance 10.3 IFNG IL2RA TNF
48 hidradenitis 10.3 CRP HLA-DRB1 IL1B PTGS2
49 rift valley fever 10.3 CRP IFNG IL1B TNF
50 patau syndrome 10.3 CRP HLA-DRB1 IL1B TNF

Graphical network of the top 20 diseases related to Rheumatic Disease:



Diseases related to Rheumatic Disease

Symptoms & Phenotypes for Rheumatic Disease

UMLS symptoms related to Rheumatic Disease:


musculoskeletal symptom, myalgia, joint symptom

GenomeRNAi Phenotypes related to Rheumatic Disease according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-104 9.64 IL2RA
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-109 9.64 HMGB1
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-134 9.64 IL2RA
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-153 9.64 SSB HMGB1
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-173 9.64 SSB IL10
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-179 9.64 SSB HMGB1 IL10 IL2RA
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-181 9.64 HMGB1 IL2RA
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-213 9.64 IL2RA
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-27 9.64 SSB
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-34 9.64 IL10 IL2RA
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-53 9.64 IL10
12 Decreased shRNA abundance (Z-score < -2) GR00366-A-65 9.64 SSB IL10
13 Decreased shRNA abundance (Z-score < -2) GR00366-A-68 9.64 IL10

MGI Mouse Phenotypes related to Rheumatic Disease:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.21 CD163 IFNG IL10 IL1B IL1R1 IL2RA
2 cardiovascular system MP:0005385 10.14 CD163 CRP IFNG IL10 IL1B IL1R1
3 homeostasis/metabolism MP:0005376 10.13 OSM PTGS1 PTGS2 TNF TRIM21 VCAM1
4 immune system MP:0005387 10.13 VCAM1 CD163 CRP IFNG IL10 IL1B
5 integument MP:0010771 9.81 IL1B IL1R1 OSM PTGS1 PTGS2 TNF
6 mortality/aging MP:0010768 9.77 IFNG IL10 IL1B IL1R1 IL2RA PTGS1
7 neoplasm MP:0002006 9.17 IFNG IL10 IL1B IL1R1 PTGS1 PTGS2

Drugs & Therapeutics for Rheumatic Disease

Drugs for Rheumatic Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 844)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Methotrexate Approved Phase 4,Phase 3,Phase 2,Phase 1 1959-05-2, 59-05-2 126941
2
Hydroxychloroquine Approved Phase 4,Phase 3,Phase 2,Phase 1 118-42-3 3652
3
Infliximab Approved Phase 4,Phase 3,Phase 2,Phase 1 170277-31-3
4
Methylprednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 83-43-2 6741
5
Naltrexone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2 16590-41-3 5360515
6
Prednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 50-24-8 5755
7
Sulfasalazine Approved Phase 4,Phase 3,Phase 2 599-79-1 5353980 5359476
8
Etanercept Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 185243-69-0
9
Leflunomide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 75706-12-6 3899
10
Methyclothiazide Approved Phase 4 135-07-9 4121
11
Hyaluronic acid Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 9004-61-9 53477741 24759
12
Milnacipran Approved Phase 4,Phase 2,Phase 3,Phase 1 92623-85-3 65833
13
Norepinephrine Approved Phase 4,Phase 3,Phase 2,Phase 1 51-41-2 439260
14
Rivaroxaban Approved Phase 4,Phase 3 366789-02-8
15
Tranexamic Acid Approved Phase 4,Phase 3,Phase 2,Phase 1 1197-18-8 5526
16
Tranylcypromine Approved Phase 4 155-09-9 441233
17
Celecoxib Approved, Investigational Phase 4,Phase 3,Phase 2 169590-42-5 2662
18
Naproxen Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 22204-53-1 1302 156391
19
Nabumetone Approved Phase 4 42924-53-8 4409
20
Spironolactone Approved Phase 4 1952-01-7, 52-01-7 5833
21
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 50-02-2 5743
22
Ropivacaine Approved Phase 4,Phase 2,Phase 3 84057-95-4 71273 175805
23
Denosumab Approved Phase 4,Phase 2,Phase 1 615258-40-7
24
Cimetidine Approved Phase 4,Phase 3,Phase 2 51481-61-9 2756
25
Hyoscyamine Approved Phase 4 101-31-5 64692
26
Etoricoxib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 202409-33-4 123619
27
Benzocaine Approved Phase 4,Phase 3,Phase 2,Phase 1 1994-09-7, 94-09-7 2337
28
Adalimumab Approved Phase 4,Phase 3,Phase 2,Phase 1 331731-18-1 16219006
29
Fluorouracil Approved Phase 4 51-21-8 3385
30
Triamcinolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 124-94-7 31307
31
Diclofenac Approved, Vet_approved Phase 4,Phase 3,Phase 2,Early Phase 1 15307-86-5 3033
32
Abatacept Approved Phase 4,Phase 3,Phase 2,Phase 1 332348-12-6 10237
33
rituximab Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 174722-31-7 10201696
34
Amitriptyline Approved Phase 4,Phase 2,Phase 3,Phase 1 50-48-6 2160
35
Cyclobenzaprine Approved Phase 4,Phase 3,Phase 2 303-53-7 2895
36
Certolizumab pegol Approved Phase 4,Phase 3,Phase 2,Phase 1 428863-50-7
37
Acetaminophen Approved Phase 4,Phase 3,Phase 2,Phase 1 103-90-2 1983
38
Tramadol Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 27203-92-5 33741
39
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 53-03-2 5865
40
Betamethasone Approved, Vet_approved Phase 4,Phase 3 378-44-9 9782
41
Cyclosporine Approved, Investigational, Vet_approved Phase 4,Phase 3 79217-60-0, 59865-13-3 5284373 6435893
42
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 22916-47-8 4189
43
Ibuprofen Approved Phase 4,Phase 3,Phase 2,Phase 1 15687-27-1 3672
44
Lidocaine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 137-58-6 3676
45
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 3,Phase 2 437-38-7 3345
46
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1 51-61-6, 62-31-7 681
47
Pregabalin Approved, Illicit, Investigational Phase 4,Phase 3,Phase 2,Phase 1 148553-50-8 5486971
48
Meloxicam Approved, Vet_approved Phase 4,Phase 3,Phase 2 71125-38-7 5281106 54677470
49
Memantine Approved, Investigational Phase 4,Phase 3 19982-08-2 4054
50
Bupivacaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 2180-92-9, 38396-39-3 2474

Interventional clinical trials:

(show top 50) (show all 5000)
id Name Status NCT ID Phase
1 Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases Unknown status NCT01151644 Phase 4
2 Effects of Different Anti-rheumatic Treatments of Arthritis on Antibody Response Following Pneumococcal Vaccination Using Prevenar® Unknown status NCT00828997 Phase 4
3 Hanyang University Medical Center Arthritis Network Unknown status NCT00418405 Phase 4
4 Uncontrolled Study to Evaluate Efficacy of Tocilizumab in Patients With Moderate or Severe Rheumatoid Arthritis Unknown status NCT02087696 Phase 4
5 Vaccination Against Pertussis, Tetanus and Diphtheria in Patients Suffering From Rheumatoid Arthritis Unknown status NCT01301703 Phase 4
6 TNF-blocking Therapy in Combination With Disease-modifying Antirheumatic Drugs in Early Rheumatoid Arthritis Unknown status NCT00908089 Phase 4
7 Remission Induction in Very Early Rheumatoid Arthritis Unknown status NCT00523692 Phase 4
8 Efficacy Study of Leflunomide to Treat Juvenile Idiopathic Arthritis Unknown status NCT02024334 Phase 4
9 Targeting Synovitis in Early Rheumatoid Arthritis Unknown status NCT00920478 Phase 4
10 A Randomised Single Centre Study to Compare the Long-Term Wear Characteristics of Marathon™ and Enduron™ Polyethylene Cup Liners in Primary Total Hip Replacement Unknown status NCT00208442 Phase 4
11 The Effect of Intraaricular Knee Injections of Hyaluronic Acid (HA) on Bone and Cartilaginous Debris, as a Therapeutic Indicator Unknown status NCT00422643 Phase 4
12 Validation of a Stress Device for the Knee Unknown status NCT02444663 Phase 4
13 Study to Evaluate the Efficacy of Milnacipran in the Treatment of Pain Due to Osteoarthritis Unknown status NCT01329406 Phase 4
14 Multi-center Clinical Study of Guli Capsules in the Treatment of Knee Osteoarthritis Unknown status NCT02484508 Phase 4
15 Comparison of Topical and Infusion Tranexamic Acid After Total Knee Arthroplasty Unknown status NCT02453802 Phase 4
16 Gastro-protective Effect and Pain Relief Effect of Naxozol Compared to Celecoxib in Patients With Osteoarthritis Unknown status NCT02355236 Phase 4
17 Medical Chitosan or Sodium Hyaluronate for Knee Osteoarthritis (CHOOSE) Unknown status NCT02323451 Phase 4
18 Tranexamic Acid in Knee Joint Surgery Unknown status NCT02278263 Phase 4
19 Comparison of Floseal® and Tranexamic Acid on Bleeding Control After Total Knee Arthroplasty Unknown status NCT02152917 Phase 4
20 Intraarticular Xylitol Injections for Knee Osteoarthritis Unknown status NCT02104596 Phase 4
21 To Compare the Efficacy and Safety of LAYLA in Osteoarthritis Patients of the Knee Unknown status NCT02049606 Phase 4
22 The Effect of Spironolactone on Pain in Older People With Osteoarthritis Unknown status NCT02046668 Phase 4
23 Outcome Comparison of Allograft and Synthetic Bone Substitute in High Tibial Osteotomy Unknown status NCT02000297 Phase 4
24 A Phase 4 Study of Imrecoxib in Treatment of Knee Osteoarthritis Unknown status NCT01985165 Phase 4
25 Comparison of Femoral Nerve Catheter and Adductor Canal Block With Steroid Adjuvant in Total Knee Replacement (TKR) Unknown status NCT01973530 Phase 4
26 Denosumab in Enhancement of Bone Bonding of Hip Prosthesis in Postmenopausal Women Unknown status NCT01926158 Phase 4
27 Reinflation After Early Tourniquet Release in Total Knee Arthroplasty Unknown status NCT01832272 Phase 4
28 Hip Viscosupplementation: What is the Best Dosage? Unknown status NCT01810809 Phase 4
29 Bone Forming at Prosthetic Surfaces. Fingerprint2 Unknown status NCT01623687 Phase 4
30 RSA Study Using Two Types of Uncemented Acetabular Components and the Uncemented HA Coated Symax Stem Unknown status NCT01618084 Phase 4
31 Chondroitin Sulphate Treatment Efficacy in Rhizarthrosis. Unknown status NCT01233739 Phase 4
32 Assessment of the Effects of Chondroitin Sulphate in Patients With Knee Osteoarthritis With Functional Magnetic Resonance Imaging (fMRI) Unknown status NCT01226615 Phase 4
33 Comparison of Outcomes in Mobile and Fixed-bearing Total Knee Arthroplasty Unknown status NCT01027819 Phase 4
34 The Impact of Hyaluronic Acid Injections on Osteoarthritic Knee Mechanics Unknown status NCT00778076 Phase 4
35 Use of Cold and Compression Therapy With Total Knee Replacement Patients Unknown status NCT00712816 Phase 4
36 Trial Comparing Navigated and Conventional Implantation Techniques in Knee Replacement Surgery Unknown status NCT00431509 Phase 4
37 Effectiveness Study of Hylan G-F 20 to Preserve Cartilage in Osteoarthritis of the Knee Unknown status NCT00393393 Phase 4
38 Effect of Flex-a-New on Osteoarthritis of the Knee Unknown status NCT00294801 Phase 4
39 Comparing Clinical Outcome of 2 Different Total Knee Prostheses: Nexgen LPS-Flex Versus AGC Unknown status NCT00294528 Phase 4
40 Efficacy of Celecoxib Vs Placebo to Prevent Pain in a Paced Walk Unknown status NCT00194090 Phase 4
41 Hyaluronan Versus NaCl 20 Ml Versus Placebo in Knee Osteoarthritis Unknown status NCT00144820 Phase 4
42 A Randomized Controlled Trial of Long Versus Short Wait For Primary Total Hip and Knee Arthroplasty Unknown status NCT00138892 Phase 4
43 Study Assessing the Efficacy of Etoricoxib in Female Patients With Fibromyalgia Unknown status NCT00755521 Phase 4
44 Study of Fibromyalgia Treated With Milnacipran Unknown status NCT01125423 Phase 4
45 Bipolar Sealer Aquamantys Use in Total Knee Replacement Unknown status NCT01736644 Phase 4
46 Comparison Between Anterior and Direct Lateral Approach in Total Hip Arthroplasty Unknown status NCT01578746 Phase 4
47 Obesity Cohort : Medical Follow-up of Severe or Morbid Obese Patients Undergoing Bariatric Surgery Unknown status NCT02310178 Phase 4
48 Danish Multicenter Study of Adalimumab in Spondyloarthritis Unknown status NCT00477893 Phase 4
49 Evaluation Effects of Treatment With IL-6R Inhibitor on Clinical Response and Biomarkers in Patients With Rheumatoid Arthritis (RA) Not Responding to DMARDs and/or a First Biological Agent. Unknown status NCT01835613 Phase 4
50 Keloid Scarring: Treatment and Pathophysiology Unknown status NCT01295099 Phase 4

Search NIH Clinical Center for Rheumatic Disease

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Genetic Tests for Rheumatic Disease

Anatomical Context for Rheumatic Disease

MalaCards organs/tissues related to Rheumatic Disease:

39
Testes, Bone, T Cells, B Cells, Skin, Breast, Endothelial

Publications for Rheumatic Disease

Articles related to Rheumatic Disease:

(show top 50) (show all 851)
id Title Authors Year
1
Fatigue and psychosocial variables in autoimmune rheumatic disease and chronic fatigue syndrome: A cross-sectional comparison. ( 27998507 )
2017
2
Robot-Assisted Mitral Valve Repair With Posterior Leaflet Extension for Rheumatic Disease. ( 28085691 )
2017
3
Paediatric rheumatic disease: Systemic JIA genetically distinct. ( 28077866 )
2017
4
The signaling adaptor TRAF1 negatively regulates Toll-like receptor signaling and this underlies its role in rheumatic disease. ( 27893701 )
2017
5
Ehlers-Danlos syndrome hypermobility type is associated with rheumatic diseases. ( 28051109 )
2017
6
Causes and consequences of endoplasmic reticulum stress in rheumatic disease. ( 27904144 )
2017
7
Development, Sensibility, and Validity of a Systemic Autoimmune Rheumatic Disease Case Ascertainment Tool. ( 27803141 )
2017
8
Genotyping of relapsing polychondritis identified novel susceptibility HLA alleles and distinct genetic characteristics from other rheumatic diseases. ( 27241705 )
2016
9
Systematic review of rheumatic disease phenotypes and outcomes in the Indigenous populations of Canada, the USA, Australia and New Zealand. ( 27988789 )
2016
10
Prevalence and clinical significance of nonorgan specific antibodies in patients with autoimmune thyroiditis as predictor markers for rheumatic diseases. ( 27661011 )
2016
11
Mediators of inflammation and bone remodeling in rheumatic disease. ( 26481971 )
2016
12
The Sphinx's riddle: cardiovascular involvement in autoimmune rheumatic disease. ( 27793103 )
2016
13
Plasma vitamin D levels and inflammation in the aortic wall of patients with coronary artery disease with and without inflammatory rheumatic disease. ( 27379927 )
2016
14
Switch from infliximab to infliximab biosimilar: efficacy and safety in a cohort of patients with different rheumatic diseasesResponse to: Nikiphorou E, Kautiainen H, Hannonen P, et al. Clinical effectiveness of CT-P13 (Infliximab biosimilar) used as a switch from Remicade (infliximab) in patients with established rheumatic disease. Report of clinical experience based on prospective observational data. Expert Opin Biol Ther. 2015;15:1677-1683. ( 27266338 )
2016
15
Interleukin-1 function and role in rheumatic disease. ( 26656658 )
2016
16
Fine particulate air pollution and systemic autoimmune rheumatic disease in two Canadian provinces. ( 26724462 )
2016
17
Involvement of the multidisciplinary team and outcomes in inpatient rehabilitation among patients with inflammatory rheumatic disease. ( 26762160 )
2016
18
Paediatric rheumatic disease: Phenotype and prognosis of juvenile systemic lupus erythematosus. ( 27305850 )
2016
19
Balancing benefits and risks of glucocorticoids in rheumatic diseases and other inflammatory joint disorders: new insights from emerging data. An expert consensus paper from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). ( 26746234 )
2016
20
Systematic review of rheumatic disease epidemiology in the indigenous populations of Canada, the United States, Australia, and New Zealand. ( 27914688 )
2016
21
Cerebrovascular Disease in Rheumatic Diseases: A Systematic Review and Meta-Analysis. ( 26917565 )
2016
22
TNF inhibitors increase fat mass in inflammatory rheumatic disease: a systematic review with meta-analysis. ( 27974099 )
2016
23
Underlying Rheumatic Disease: An Important Determinant of Outcome in Tricuspid Valve Repair. ( 27989068 )
2016
24
Evaluation of interferon-gamma release assay (T-SPOT.TB(a8c) ) for diagnosis of tuberculosis infection in rheumatic disease patients. ( 26820838 )
2016
25
Nutrition and chronic inflammatory rheumatic disease. ( 27914804 )
2016
26
NMR-based metabolomic approach to study urine samples of chronic inflammatory rheumatic disease patients. ( 27900420 )
2016
27
The metabolic role of the gut microbiota in health and rheumatic disease: mechanisms and interventions. ( 27256713 )
2016
28
Prevalence of musculoskeletal disorders and rheumatic disease in the Warao, Kari'A+a, and Chaima indigenous populations of Monagas State, Venezuela. ( 26895629 )
2016
29
Early Onset of Chronic Rheumatic Disease May Lead to Creative Expression: The Stories of Antoni GaudA- and Maud Lewis. ( 27371648 )
2016
30
Association between Air Pollution and the Development of Rheumatic Disease: A Systematic Review. ( 27847517 )
2016
31
The Role of Autophagy in Rheumatic Disease. ( 27550202 )
2016
32
Patients suffering from rheumatic disease describing own experiences from participating in Basic Body Awareness Group Therapy: A qualitative pilot study. ( 26863582 )
2016
33
Usability and Workflow Evaluation of "RhEumAtic Disease activitY" (READY). A Mobile Application for Rheumatology Patients and Providers. ( 27803949 )
2016
34
Single-cell antibody nanowells: a novel technology in detecting anti-SSA/Ro60- and anti-SSB/La autoantibody-producing cells in peripheral blood of rheumatic disease patients. ( 27184054 )
2016
35
Survival rates of cancer patients with and without rheumatic disease: a retrospective cohort analysis. ( 27412038 )
2016
36
Th9 lymphocytes: A recent history from IL-9 to its potential role in rheumatic diseases. ( 26921642 )
2016
37
Association between demyelinating disease and autoimmune rheumatic disease in a pediatric population. ( 27746022 )
2016
38
Association between TYK2 polymorphisms and susceptibility to autoimmune rheumatic diseases: a meta-analysis. ( 26980740 )
2016
39
The microbiota in pediatric rheumatic disease: epiphenomenon or therapeutic target? ( 27286235 )
2016
40
Prevalence and the clinical outcome of atrial fibrillation in patients with Autoimmune Rheumatic Disease. ( 27055157 )
2016
41
Usefulness of two interferon-I^ release assays for rheumatic disease. ( 26670306 )
2016
42
Current and emerging treatment options for interstitial lung disease in patients with rheumatic disease. ( 26752397 )
2016
43
Influence of anti-TNF immunogenicity on safety in rheumatic disease: a narrative review. ( 27924646 )
2016
44
Incidence of hepatitis B virus reactivation in patients with resolved infection on immunosuppressive therapy for rheumatic disease: a multicentre, prospective, observational study in Japan. ( 27934678 )
2016
45
Rheumatic Disease Autoantibodies in Autoimmune Liver Diseases. ( 27409579 )
2016
46
Autoimmune vitiligo in rheumatic disease in the mestizo Mexican population. ( 27446537 )
2016
47
Patterns and consequences of multimorbidity in the general population: There is no chronic disease management without rheumatic disease management. ( 27482954 )
2016
48
Alendronate prevents glucocorticoid-induced osteoporosis in patients with rheumatic diseases: A meta-analysis. ( 27336902 )
2016
49
[Correlation between the genetic polymorphisms of apolipoprotein M with the susceptibility to rheumatic diseases of Chinese Han populastion in Lanzhou]. ( 27412944 )
2016
50
Gout: will the "King of Diseases" be the first rheumatic disease to be cured? ( 27832792 )
2016

Variations for Rheumatic Disease

Expression for Rheumatic Disease

Search GEO for disease gene expression data for Rheumatic Disease.

Pathways for Rheumatic Disease

Pathways related to Rheumatic Disease according to GeneCards Suite gene sharing:

(show top 50) (show all 57)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
14.07 CRP HLA-DRB1 HMGB1 IFNG IL10 IL1B
2
Show member pathways
13.7 IFNG IL10 IL1B IL1R1 IL2RA OSM
3
Show member pathways
13.23 HLA-DRB1 HMGB1 IFNG IL1B IL1R1 IL2RA
4
Show member pathways
13.04 HLA-DRB1 IFNG IL10 IL1B IL1R1 IL2RA
5
Show member pathways
12.9 HLA-DRB1 IFNG IL10 IL1B IL2RA TNF
6
Show member pathways
12.81 HLA-DRB1 IFNG IL1B IL2RA TNF
7
Show member pathways
12.66 HLA-DRB1 IFNG IL10 IL2RA TNF
8
Show member pathways
12.61 HLA-DRB1 IFNG IL10 IL1B IL1R1 IL2RA
9 12.48 HLA-DRB1 IL1R1 IL2RA TNF VCAM1
10
Show member pathways
12.41 IL10 PTGS2 TNFRSF11B VCAM1
11
Show member pathways
12.38 CRP IFNG IL1B PTGS1 PTGS2 TNF
12
Show member pathways
12.35 IFNG IL1B PTGS2 TNF
13 12.35 IFNG IL10 IL1B IL2RA PTGS1 PTGS2
14
Show member pathways
12.33 IFNG IL1B IL1R1 PTGS2 TNF
15 12.29 HLA-DRB1 IFNG IL10 IL1B TNF
16
Show member pathways
12.26 HLA-DRB1 IFNG IL10 IL1B PTGS2 TNF
17
Show member pathways
12.24 IFNG IL10 IL2RA OSM
18
Show member pathways
12.22 IFNG IL1B IL1R1 TNF
19
Show member pathways
12.2 IFNG IL10 IL1B TNF
20 12.16 IFNG IL1B IL1R1 TNF VCAM1
21 12.12 IFNG IL1B IL1R1 TNF TNFRSF11B
22 12.08 IFNG IL1B IL1R1 PTGS2 TNF
23 12.06 CD163 IFNG IL10 IL2RA TNF
24
Show member pathways
12.03 HLA-DRB1 IFNG IL1B IL1R1 IL2RA
25 12.01 IL1B PTGS2 TNF VCAM1
26
Show member pathways
12 IFNG IL10 IL1B TNF
27 11.94 HLA-DRB1 IL1B IL1R1 IL2RA TNF
28 11.93 IFNG IL10 IL1B IL1R1 TNF
29 11.91 HLA-DRB1 IFNG IL1B TNF
30 11.91 IL1B IL1R1 PTGS2 TNF VCAM1
31 11.9 IL10 IL1B OSM PTGS2 TNF VCAM1
32
Show member pathways
11.83 IFNG IL2RA PTGS2 TNF
33 11.79 IL10 IL2RA TNF VCAM1
34 11.78